The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway

Abstract

To explore the functional consequences of possible cross-talk between the CXCR4/CXCL12 and the sphingosine-1-phosphate (S1P) pathways in multiple myeloma (MM) cells and to evaluate the effect of S1P targeting with the FTY720 modulator as a potential anti-MM therapeutic strategy. S1P targeting with FTY720 induces MM cell apoptosis. The combination of FTY720 with the SPHK1 inhibitor SKI-II results in synergistic inhibition of MM growth. CXCR4/CXCL12-enhanced expression correlates with reduced MM cell sensitivity to both FTY720 and SKI-II inhibitors, and with SPHK1 coexpression in both cell lines and primary MM bone marrow (BM) samples, suggesting regulative cross-talk between the CXCR4/CXCL12 and SPHK1 pathways in MM cells. FTY720 was found to directly target CXCR4. FTY720 profoundly reduces CXCR4 cell-surface levels and abrogates the CXCR4-mediated functions of migration toward CXCL12 and signaling pathway activation. Moreover, FTY720 cooperates with bortezomib, inducing its cytotoxic activity and abrogating the bortezomib-mediated increase in CXCR4 expression. FTY720 effectively targets bortezomib-resistant cells and increases their sensitivity to bortezomib, promoting DNA damage. Finally, in a recently developed novel xenograft model of CXCR4-dependent systemic MM with BM involvement, FTY720 treatment effectively reduces tumor burden in the BM of MM-bearing mice. FTY720 in combination with bortezomib demonstrates superior tumor growth inhibition and abrogates bortezomib-induced CXCR4 increase on MM cells. Altogether, our work identifies a cross-talk between the S1P and CXCR4 pathways in MM cells and provides a preclinical rationale for the therapeutic application of FTY720 in combination with bortezomib in patients with MM. .

The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives

“…The anti-leukemic effect of fingolimod occurred in cooperation with bortezomib and the molecular data suggest a cross-talk between the S1P and the CXCR4 pathways (Beider et al, 2017). However, inhibition of CXCR4 determined by analysis of intracellular survival signaling via extracellular signal-regulated protein kinase (ERK)1/2 and S6 proteins was measured at a concentration of 20 µM fingolimod without showing data from lower doses at which cell viability was already decreased.…”

“…Current preclinical data suggest that a downside of fingolimod for cancer therapy is its low efficacy and potency. In vitro, biological responses in cancer cells were reported at µM concentrations, and in tumor xenograft models in mice, anti-tumor activity was always measured after daily injections of aberrantly high doses, ranging from 2.5-10 mg/kg (Beider et al, 2017;Cristobal et al, 2014;Gstalder et al, 2016;Pchejetski et al, 2010;Rincon et al, 2015). This is up to 1400-fold more than used in patients to treat MS, and it is clear that at such high doses numerous targets are affected which are crucial for normal tissue function.…”

Sphingosine kinase 1 participates in the activation, proliferation and survival of chronic lymphocytic leukemia cells

“…4 Carmen Stanganelli, 5 Irma Slavutsky, 6 María Cabrejo, 7 Horacio Fernández-Grecco, 7 Raimundo Fernando Bezares, 8 Santiago Cranco, 9 Rubén Ángel Burgos, 9 Julio César Sánchez-Ávalos, 9 Pablo Oppezzo, 10 Mirta Giordano 1,3 and Romina Gamberale …”

Sphingosine‐1‐phosphate (S1P) receptors: Promising drug targets for treating bone‐related diseases

“…In addition to the role of S1P as a first or second messenger that regulates cell migration, differentiation, proliferation and apoptosis, we focused on osteoclast‐osteoblast crosstalk coupled with S1P 92 . Interestingly, FTY720 acts as an inhibitor of the S1P receptor and was tested in clinical experiments in 2017 93 . In addition, S1P acts as a bridge linking macrophages with inflammatory osteolysis and bone metastasis, which provides us with a novel drug target.…”